Journal of Gastroenterology

, Volume 52, Issue 4, pp 483–493

Development of a scoring system for differentiating IgG4-related sclerosing cholangitis from primary sclerosing cholangitis

  • Sung-Hoon Moon
  • Myung-Hwan Kim
  • Jong Kyun Lee
  • Seunghee Baek
  • Young Sik Woo
  • Dong Hui Cho
  • Dongwook Oh
  • Tae Jun Song
  • Do Hyun Park
  • Sang Soo Lee
  • Dong Wan Seo
  • Sung Koo Lee
Original Article—Liver, Pancreas, and Biliary Tract



Recent research has shown that a substantial number of patients with primary sclerosing cholangitis (PSC) can also have elevated serum/tissue IgG4. The aim of our study was to develop a simple scoring system for the discrimination of IgG4-related sclerosing cholangits (IgG4-SC) from PSC.


Patients with IgG4-SC (n = 39) and PSC (n = 76) who had intrahepatic/hilar strictures were included. Candidate-differentiating variables included patient age, other organ involvement (OOI), inflammatory bowel disease, serum IgG4, and cholangiographic features. A scoring system was developed on the basis of these variables, and its performance was internally validated using a bootstrapping-based method.


The scoring system in the final model included age (<30 years, 0 points; 30–39 years, 1 point; 40–49 years, 2 points; 50–59 years, 3 points; ≥60 years, 4 points), OOI (no, 0 points; yes, 3 points), and beaded appearance (yes, 0 points; no, 2 points). The patients were classified according to their total score into three categories: 0–4 points, probable PSC; 5–6 points, indicating diagnostic steroid trial; 7–9 points, probable IgG4-SC. The discrimination between IgG4-SC and PSC using the scoring system was excellent (area under the receiver operating characteristic curve, 0.986).


A reliable differentiation of IgG4-SC from PSC can be made using the scoring system presented here. We suggest the diagnosis of IgG4-SC at a cutoff of 7 points or higher and the indication of diagnostic steroid trial at 5 or 6 points. External validation of our scoring system is warranted.


IgG4-related sclerosing cholangitis Primary sclerosing cholangitis Diagnosis Scoring system 

Supplementary material

535_2016_1246_MOESM1_ESM.tif (74 kb)
Supplementary Fig. 1. Capability of the scoring system to differentiate between IgG4-related sclerosing cholangitis and primary sclerosing cholangitis. The area under the receiver operating characteristic curve of the scoring system was 0.986 (TIFF 74 kb)
535_2016_1246_MOESM2_ESM.docx (16 kb)
Supplementary material 2 (DOCX 15 kb)
535_2016_1246_MOESM3_ESM.docx (14 kb)
Supplementary material 3 (DOCX 13 kb)
535_2016_1246_MOESM4_ESM.docx (15 kb)
Supplementary material 4 (DOCX 14 kb)


  1. 1.
    Karlsen TH, Boberg KM. Update on primary sclerosing cholangitis. J Hepatol. 2013;59:571–82.CrossRefPubMedGoogle Scholar
  2. 2.
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237–67.Google Scholar
  3. 3.
    Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660–78.CrossRefPubMedGoogle Scholar
  4. 4.
    Hirschfield GM, Karlsen TH, Lindor KD, et al. Primary sclerosing cholangitis. Lancet. 2013;382:1587–99.CrossRefPubMedGoogle Scholar
  5. 5.
    Lindor KD, Kowdley KV, Harrison ME. ACG Clinical Guideline: primary sclerosing cholangitis. Am J Gastroenterol. 2015;110:646–59.CrossRefPubMedGoogle Scholar
  6. 6.
    Okazaki K, Uchida K, Koyabu M, et al. IgG4 cholangiopathy—current concept, diagnosis, and pathogenesis. J Hepatol. 2014;61:690–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Ponsioen CY. Diagnosis, differential diagnosis, and epidemiology of primary sclerosing cholangitis. Dig Dis. 2015;33(Suppl 2):134–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Boonstra K, Culver EL, de Buy Wenniger LM, et al. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology. 2014;59:1954–63.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Culver EL, Chapman RW. Systematic review: management options for primary sclerosing cholangitis and its variant forms—IgG4-associated cholangitis and overlap with autoimmune hepatitis. Aliment Pharmacol Ther. 2011;33:1273–91.CrossRefPubMedGoogle Scholar
  10. 10.
    Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706–15.CrossRefPubMedGoogle Scholar
  11. 11.
    Bonato G, Cristoferi L, Strazzabosco M, et al. Malignancies in primary sclerosing cholangitis—a continuing threat. Dig Dis. 2015;33(Suppl 2):140–8.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Bjornsson E, Chari ST, Smyrk TC, et al. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology. 2007;45:1547–54.CrossRefPubMedGoogle Scholar
  13. 13.
    Takikawa H, Takamori Y, Tanaka A, et al. Analysis of 388 cases of primary sclerosing cholangitis in Japan; presence of a subgroup without pancreatic involvement in older patients. Hepatol Res. 2004;29:153–9.CrossRefPubMedGoogle Scholar
  14. 14.
    de Valle MB, Muller T, Bjornsson E, et al. The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis. Dig Liver Dis. 2014;46:903–8.CrossRefGoogle Scholar
  15. 15.
    Bjornsson E, Chari S, Silveira M, et al. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther. 2011;18:198–205.CrossRefPubMedGoogle Scholar
  16. 16.
    Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101:2070–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Tanaka A, Tazuma S, Okazaki K, et al. Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan. J Hepatobiliary Pancreat Sci. 2014;21:43–50.CrossRefPubMedGoogle Scholar
  18. 18.
    Zhang L, Lewis JT, Abraham SC, et al. IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Am J Surg Pathol. 2010;34:88–94.CrossRefPubMedGoogle Scholar
  19. 19.
    Deheragoda MG, Church NI, Rodriguez-Justo M, et al. The use of immunoglobulin g4 immunostaining in diagnosing pancreatic and extrapancreatic involvement in autoimmune pancreatitis. Clin Gastroenterol Hepatol. 2007;5:1229–34.CrossRefPubMedGoogle Scholar
  20. 20.
    Moon SH, Kim MH. The role of endoscopy in the diagnosis of autoimmune pancreatitis. Gastrointest Endosc. 2012;76:645–56.CrossRefPubMedGoogle Scholar
  21. 21.
    Ohara H, Okazaki K, Tsubouchi H, et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci. 2012;19:536–42.CrossRefPubMedGoogle Scholar
  22. 22.
    Park DH, Kim MH. Intrapancreatic common bile duct involvement of autoimmune pancreatitis: is it really IgG4-associated cholangitis? Gastroenterology. 2008;135:324–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Chari ST, Smyrk TC, Levy MJ, et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol. 2006;4:1010–6 (quiz 934).CrossRefPubMedGoogle Scholar
  24. 24.
    Nakazawa T, Ohara H, Sano H, et al. Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. Gastrointest Endosc. 2004;60:937–44.CrossRefPubMedGoogle Scholar
  25. 25.
    Kim JH, Byun JH, Kim SY, et al. Sclerosing cholangitis with autoimmune pancreatitis versus primary sclerosing cholangitis: comparison on endoscopic retrograde cholangiography, MR cholangiography, CT, and MRI. Acta Radiol. 2013;54:601–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25:1181–92.CrossRefPubMedGoogle Scholar
  27. 27.
    Steyerberg EW, Harrell FE Jr, Borsboom GJ, et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54:774–81.CrossRefPubMedGoogle Scholar
  28. 28.
    Sullivan LM, Massaro JM, D’Agostino RB Sr. Presentation of multivariate data for clinical use: the Framingham study risk score functions. Stat Med. 2004;23:1631–60.CrossRefPubMedGoogle Scholar
  29. 29.
    Abdalian R, Heathcote EJ. Sclerosing cholangitis: a focus on secondary causes. Hepatology. 2006;44:1063–74.CrossRefPubMedGoogle Scholar
  30. 30.
    Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58:2045–55.CrossRefPubMedGoogle Scholar
  31. 31.
    Molodecky NA, Kareemi H, Parab R, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53:1590–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Kamisawa T, Egawa N, Tsuruta K, et al. Primary sclerosing cholangitis may be overestimated in Japan. J Gastroenterol. 2005;40:318–9.CrossRefPubMedGoogle Scholar
  33. 33.
    van Buuren HR, Vleggaar FP, Willemien Erkelens G, et al. Autoimmune pancreatocholangitis: a series of ten patients. Scand J Gastroenterol. 2006;41(Suppl 243):70–8.CrossRefGoogle Scholar
  34. 34.
    Beuers U, Hubers LM, Doorenspleet M, et al. IgG4-associated cholangitis—a mimic of PSC. Dig Dis. 2015;33(Suppl 2):176–80.CrossRefPubMedGoogle Scholar
  35. 35.
    Huggett MT, Culver EL, Kumar M, et al. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. Am J Gastroenterol. 2014;109:1675–83.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Ohara H, Nakazawa T, Kawa S, et al. Establishment of a serum IgG4 cut-off value for the differential diagnosis of IgG4-related sclerosing cholangitis: a Japanese cohort. J Gastroenterol Hepatol. 2013;28:1247–51.CrossRefPubMedGoogle Scholar
  37. 37.
    Eaton JE, Talwalkar JA, Lazaridis KN, et al. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology. 2013;145:521–36.CrossRefPubMedGoogle Scholar
  38. 38.
    Kamisawa T, Zen Y, Pillai S, et al. IgG4-related disease. Lancet. 2015;385:1460–71.CrossRefPubMedGoogle Scholar
  39. 39.
    Nakazawa T, Naitoh I, Hayashi K, et al. Diagnostic criteria for IgG4-related sclerosing cholangitis based on cholangiographic classification. J Gastroenterol. 2012;47:79–87.CrossRefPubMedGoogle Scholar
  40. 40.
    Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut. 2002;51:562–6.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Kalaitzakis E, Levy M, Kamisawa T, et al. Endoscopic retrograde cholangiography does not reliably distinguish IgG4-associated cholangitis from primary sclerosing cholangitis or cholangiocarcinoma. Clin Gastroenterol Hepatol. 2011;9(800–3):e2.Google Scholar
  42. 42.
    Parhizkar B, Mohammad Alizadeh AH, Asadzadeh Aghdaee H, Malekpour H, Entezari AH. Primary sclerosing cholangitis associated with elevated immunoglobulin-G4: a preliminary study. ISRN Gastroenterol. 2012;2012:325743.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Kawakami H, Zen Y, Kuwatani M, et al. IgG4-related sclerosing cholangitis and autoimmune pancreatitis: histological assessment of biopsies from Vater’s ampulla and the bile duct. J Gastroenterol Hepatol. 2010;25:1648–55.CrossRefPubMedGoogle Scholar
  44. 44.
    Dave M, Elmunzer BJ, Dwamena BA, et al. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology. 2010;256:387–96.CrossRefPubMedGoogle Scholar
  45. 45.
    Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the international autoimmune hepatitis group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54:374–85.CrossRefPubMedGoogle Scholar
  46. 46.
    Parkes M, Booth JC, Pillai G, et al. Do steroids help jaundice caused by primary sclerosing cholangitis? J Clin Gastroenterol. 2001;33:319–22.CrossRefPubMedGoogle Scholar
  47. 47.
    Zenouzi R, Lohse AW. Long-term outcome in PSC/AIH “overlap syndrome”: does immunosuppression also treat the PSC component? J Hepatol. 2014;61:1189–91.CrossRefPubMedGoogle Scholar
  48. 48.
    Nakazawa T, Naitoh I, Ando T, et al. A case of advanced-stage sclerosing cholangitis with autoimmune pancreatitis not responsive to steroid therapy. JOP. 2010;11:58–60.PubMedGoogle Scholar
  49. 49.
    Vosskuhl K, Negm AA, Framke T, et al. Measurement of IgG4 in bile: a new approach for the diagnosis of IgG4-associated cholangiopathy. Endoscopy. 2012;44:48–52.CrossRefPubMedGoogle Scholar
  50. 50.
    Naitoh I, Nakazawa T, Hayashi K, et al. Comparison of intraductal ultrasonography findings between primary sclerosing cholangitis and IgG4-related sclerosing cholangitis. J Gastroenterol Hepatol. 2015;30:1104–9.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2016

Authors and Affiliations

  • Sung-Hoon Moon
    • 1
  • Myung-Hwan Kim
    • 2
  • Jong Kyun Lee
    • 3
  • Seunghee Baek
    • 4
  • Young Sik Woo
    • 3
  • Dong Hui Cho
    • 2
  • Dongwook Oh
    • 2
  • Tae Jun Song
    • 2
  • Do Hyun Park
    • 2
  • Sang Soo Lee
    • 2
  • Dong Wan Seo
    • 2
  • Sung Koo Lee
    • 2
  1. 1.Department of Internal Medicine, Hallym University College of MedicineHallym University Sacred Heart HospitalAnyangSouth Korea
  2. 2.Department of Internal Medicine, University of Ulsan College of MedicineAsan Medical CenterSeoulSouth Korea
  3. 3.Department of Medicine, Sungkyunkwan University School of MedicineSamsung Medical CenterSeoulSouth Korea
  4. 4.Department of Clinical Epidemiology and Biostatistics, University of Ulsan College of MedicineAsan Medical CenterSeoulSouth Korea

Personalised recommendations